Displaying 1 - 2 of 2
| Active Ingredient | EPLERENONE |
| Therapeutic Class | ALDOSTERONE RECEPTOR ANTAGONIST |
| Indications | Hypertension, Chronic heart failure (NYHA class II-IV) with reduced ejection fraction |
| Caution | Hyperkalemia, Hypercholesterolaemia, hypertriglyceridaemia |
| Dose Range | Hypertension: Initially 50mg daily increased to a maximum of 50mg twice a day. HF: Initially 25mg daily, increased in 25mg increments, if tolerated, to a maximum of 50mg daily in a 4 week period. |
| Drug Interactions | |
| Pregnancy | |
| Breast Feeding |
| Active Ingredient | SPIRONOLACTONE |
| Therapeutic Class | ALDOSTERONE RECEPTOR ANTAGONIST |
| Indications | Oedema in Congestive Heart Failure (CHF).It is frequently given with the thiazides, furosemide, or similar diuretics, where it adds to their natriuretic but diminishes their kaliuretic effects, he More ... |
| Caution |
May cause hyperkalemia in renal failure; gynaecomastia, nausea, vomiting, drowiness. C.f. prescribing in renal disease p. 36. |
| Dose Range |
Adults and Children over 12yrs: Odema: 100-200mg daily in single or divided doses to a maximum of 400mg daily. Moderate to severe heart failure (Adjunct): initially 25mg increased to a maximum of 50mg once daily . Pediatric 1mth-12yrs: 1-3mg/kg in 1 or 2 |
| Drug Interactions | |
| Pregnancy | Safe use of spironolactone during pregnancy has not been established. The drug s More ... |
| Breast Feeding | Spironolactone enters breastmilk and is not recommended in lactating women. |